Lenvatinib Mesylate CAS 857890-39-2 Assay 98.0 ~ 102.0% Factory
Ipese Kemikali Ruifu Lenvatinib Mesylate Intermediates Pẹlu Iwa mimọ to gaju
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1- (2-Chloro-4-Hydroxyphenyl) -3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5- (Methoxymethylene) -2,2-Dimethyl-1,3-Dioxane-4,6-Dion CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Orukọ Kemikali | Lenvatinib Mesylate |
Awọn itumọ ọrọ sisọ | 4- [3-Chloro-4-[(cyclopropylaminocarbonyl) amino] phenoxy] -7-Methoxy-6-Quinolinecarboxamide Mesylate;E 7080 Mesylate;Lenvima |
Nọmba CAS | 857890-39-2 |
NỌMBA CAT | RF-PI1975 |
Iṣura Ipo | Ninu Iṣura, Iwọn iṣelọpọ Ti o to Awọn Toonu |
Fọọmu Molecular | C21H19N4O4Cl.CH4O3S |
Òṣuwọn Molikula | 522.96 |
Brand | Ruifu Kemikali |
Nkan | Awọn pato |
Ifarahan | Funfun si Paa-White Powder tabi kirisita |
Idanimọ | Nipasẹ IR;Nipasẹ UV;Nipasẹ HPLC |
Solubility | Tiotuka die-die ninu Omi, Ailesolusan Ni Ethanol |
Ojuami Iyo | 228.0 ~ 230.0 ℃ |
Akoonu Omi (KF) | <1.00% |
Aloku lori Iginisonu | <0.10% |
Awọn irin Heavy | <20ppm |
Awọn nkan ti o jọmọ | |
Eyikeyi Nikan Aimọ | <0.50% |
Lapapọ Awọn Aimọ | <1.00% |
Aseyori / Analysis Ọna | 98.0 ~ 102.0% (HPLC Ipilẹ lori Gbigbe) |
Olopobobo iwuwo | 0.40gm/ml ~0.60gm/ml |
Igbeyewo Standard | Standard Enterprise |
Lilo | API |
Package: Igo, apo bankanje aluminiomu, 25kg / Paali ilu, tabi gẹgẹ bi ibeere alabara
Ipò Ìpamọ́:Fipamọ sinu awọn apoti ti a fi edidi ni itura ati ibi gbigbẹ;Dabobo lati ina ati ọrinrin
Lenvatinib Mesylate (CAS: 857890-39-2) jẹ inhibitor oral ati olona-fojusi ti VEGFR1-3, FGFR1-4, PDGFR, KIT, ati RET, pẹlu awọn iṣẹ antitumor ti o lagbara.Lenvatinib Mesylate jẹ oludena tyrosine kinase (RTK) olugba ti o ni yiyan fun VEGFR2.O ṣe afihan iṣẹ-ṣiṣe antineoplastic, ati pe o ti ni itọkasi fun itọju awọn alaisan ti o ni atunṣe ti agbegbe tabi metastatic, ilọsiwaju, iodine radioactive (RAI) -refractory differentiated tairodu akàn.Lenvatinib Mesylate ni akọkọ fọwọsi nipasẹ Ile-iṣẹ Ounje ati Oògùn AMẸRIKA (FDA) ni Oṣu kejila ọjọ 13, ọdun 2015, lẹhinna fọwọsi nipasẹ Ile-iṣẹ elegbogi ati Awọn Ẹrọ Iṣoogun ti Japan (PMDA) ni Oṣu Kẹta Ọjọ 26, Ọdun 2015, ati fọwọsi nipasẹ Ile-iṣẹ Oogun Yuroopu (EMA) lori Oṣu Karun ọjọ 28, Ọdun 2015. O jẹ idagbasoke ati tita bi Lenvima® nipasẹ Eisai.Lenvatinib Mesylate jẹ inhibitor ọpọ olugba tyrosine kinase ti oral pẹlu ipo abuda alailẹgbẹ kan ti o yan ni idinamọ awọn iṣẹ ṣiṣe kinase ti awọn olugba idagba endothelial ti iṣan (VEGF), ni afikun si awọn proangiogenic miiran ati awọn ọna oncogenic ti o ni ibatan tyrosine kinases ro pe o ni ipa ninu isunmọ tumo. .O ti wa ni itọkasi fun awọn itọju ti ilọsiwaju radioiodine-refractory differentiated tairodu akàn.Lenvimani a lo funrararẹ lati ṣe itọju akàn tairodu ti o yatọ (DTC), iru akàn tairodu ti ko le ṣe itọju pẹlu iodine ipanilara ati ti nlọsiwaju.LENVIMA ni a lo pẹlu oogun miiran ti a npe ni everolimus lati tọju awọn agbalagba ti o ni iru akàn kidinrin kan ti a npe ni carcinoma kidirin ti ilọsiwaju (RCC) lẹhin itọju kan pẹlu oogun egboogi-akàn miiran.